Comment diagnostiquer une dysrégulation des kinases à tyrosine ?

Des tests sanguins et des biopsies peuvent révéler des anomalies dans l'activité des kinases.

Quels marqueurs sont utilisés pour le diagnostic ?

Les marqueurs tumoraux comme le CA 19-9 peuvent indiquer une activité kinase anormale.

Les tests génétiques sont-ils utiles ?

Oui, ils peuvent identifier des mutations dans les gènes codant pour les kinases à tyrosine.

Quels examens d'imagerie sont recommandés ?

L'IRM et le scanner peuvent aider à visualiser les tumeurs associées aux kinases.

Les antécédents familiaux influencent-ils le diagnostic ?

Oui, des antécédents de cancers peuvent augmenter le risque de dysrégulation des kinases.

Quels symptômes sont liés à une suractivité des kinases ?

Fatigue, perte de poids, et douleurs osseuses peuvent indiquer une suractivité des kinases.

Les symptômes varient-ils selon le type de kinase ?

Oui, les symptômes dépendent du type de kinase et de la voie de signalisation affectée.

Y a-t-il des symptômes spécifiques aux cancers ?

Oui, des symptômes comme des masses palpables ou des saignements peuvent survenir.

Les symptômes peuvent-ils être confondus avec d'autres maladies ?

Oui, des symptômes comme la fatigue peuvent être communs à plusieurs maladies.

Comment les symptômes évoluent-ils dans le temps ?

Ils peuvent s'aggraver progressivement, nécessitant une surveillance régulière.

Peut-on prévenir les dysfonctionnements des kinases ?

Une alimentation saine et l'exercice régulier peuvent réduire le risque de cancers.

Les dépistages réguliers sont-ils recommandés ?

Oui, des dépistages peuvent aider à détecter précocement des anomalies liées aux kinases.

Y a-t-il des vaccins préventifs ?

Actuellement, il n'existe pas de vaccins spécifiques pour prévenir les dysfonctionnements des kinases.

Le tabagisme influence-t-il le risque ?

Oui, le tabagisme est un facteur de risque connu pour plusieurs cancers liés aux kinases.

Les facteurs environnementaux jouent-ils un rôle ?

Oui, l'exposition à des substances chimiques peut augmenter le risque de dysfonctionnement des kinases.

Quels traitements ciblent les kinases à tyrosine ?

Les inhibiteurs de kinases, comme l'imatinib, sont utilisés pour traiter certains cancers.

Les traitements sont-ils personnalisés ?

Oui, les traitements peuvent être adaptés en fonction des mutations spécifiques des kinases.

Quels effets secondaires des traitements sont courants ?

Fatigue, nausées et éruptions cutanées sont des effets secondaires fréquents.

La radiothérapie est-elle utilisée ?

Oui, la radiothérapie peut être utilisée en complément des traitements ciblés.

Les traitements sont-ils efficaces à long terme ?

L'efficacité varie, mais certains patients peuvent bénéficier d'une rémission prolongée.

Quelles complications peuvent survenir avec les kinases ?

Des complications comme la résistance aux traitements et la progression de la maladie peuvent survenir.

Les complications sont-elles réversibles ?

Certaines complications peuvent être gérées, mais d'autres peuvent être permanentes.

Comment les complications affectent-elles le pronostic ?

Les complications peuvent aggraver le pronostic et réduire les chances de rémission.

Les complications varient-elles selon le type de cancer ?

Oui, les complications peuvent différer selon le type de cancer et la kinase impliquée.

Les complications nécessitent-elles des traitements supplémentaires ?

Oui, des traitements supplémentaires peuvent être nécessaires pour gérer les complications.

Quels sont les principaux facteurs de risque ?

Les antécédents familiaux, le tabagisme et l'exposition à des produits chimiques sont des facteurs de risque.

L'âge influence-t-il le risque de dysfonctionnement des kinases ?

Oui, le risque augmente généralement avec l'âge, surtout pour certains cancers.

Le mode de vie joue-t-il un rôle ?

Oui, un mode de vie sédentaire et une mauvaise alimentation augmentent le risque.

Les infections peuvent-elles être un facteur de risque ?

Certaines infections virales, comme le virus d'Epstein-Barr, peuvent augmenter le risque.

Y a-t-il des facteurs génétiques impliqués ?

Oui, des mutations génétiques héréditaires peuvent prédisposer à des dysfonctionnements des kinases.

Protein-tyrosine kinases - Informations médicales vérifiées

Serum prostate specific antigen is a good indicator of prostatic volume in men with benign prostatic hyperplasia.

15 Dec 2022

DOI: 10.4102/phcfm.v14i1.3736 PMID: 36546488

Benign prostatic hyperplasia (BPH) is the most common cause of bladder outlet obstruction in men over the age of 50 years. An association between the prostate specific antigen (PSA), International Pro... To determine the correlation between the PSA, IPSS and PV in men of African descent.... This was a cross sectional analysis involving 92 patients diagnosed as having symptomatic BPH at the Ho Teaching Hospital.... The data were collected using standardised questionnaires. The IPSS determined urinary symptom severity. The PV was determined using a transabdominal ultrasound machine. Serum PSA was retrieved from t... The mean PV was 61.04 cm3 ± 21.95 cm3, the mean PSA was 4.21 ng/mL ± 3.85 ng/mL, and mean IPSS of 21.59 ± 3.78. The Pearson's correlation between PV and PSA was 0.283 (p = 0.01), between PV and IPSS w... This study showed that serum PSA has a positive correlation with PV. However, IPSS had no significant association with PSA or PV in patients with BPH.Contribution: This study provides insights into th...

Male Humans Middle Aged Prostatic Hyperplasia Prostate-Specific Antigen +2 autres

Granulomatous prostatitis: mimicking locally advanced prostate adenocarcinoma.

17 10 2023

DOI: 10.23750/abm.v94i5.13751 PMID: 37850783

We report the case of a 63-year-old male who came to the urology clinic with an increasing value of the prostate specific antigen and an asymmetrical enlargement at the digital rectal examination. The...

Male Humans Middle Aged Prostatitis Prostate +5 autres

Prostatic Artery Embolization Versus Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia: A Cost-Effectiveness Analysis.

12 2022

DOI: 10.1016/j.jvir.2022.08.006 PMID: 35964881

To compare the cost effectiveness of prostatic artery embolization (PAE) with that of transurethral resection of the prostate (TURP) for the treatment of medically refractory benign prostatic hyperpla... A cost-effectiveness analysis with Markov modeling was performed, comparing the clinical course after PAE with that after TURP for 3 years. Probabilities were obtained from the available literature, a... Base case calculation showed comparable outcomes (PAE, 2.845 QALY; TURP, 2.854 QALY), with a cost difference of $3,104 (PAE, $2,934; TURP, $6,038). The incremental cost-effectiveness ratio was $360,24... PAE is a cost-effective strategy to treat medically refractory BPH, resulting in comparable health benefits at a lower cost than that of TURP even when accounting for extreme alterations in adverse ev...

Aged United States Male Humans Prostatic Hyperplasia +7 autres

Prostate organogenesis.

15 06 2022

DOI: 10.1242/dev.200394 PMID: 35726824

Prostate organogenesis begins during embryonic development and continues through puberty when the prostate becomes an important exocrine gland of the male reproductive system. The specification and gr...

Androgens Epithelial Cells Epithelium Humans Male +3 autres

Prostatic Urethral Length as a Predictor for Surgery in Benign Prostatic Hyperplasia.

10 Mar 2023

DOI: 10.33314/jnhrc.v20i3.4613 PMID: 36974872

Benign prostatic hyperplasia is associated with structural and morphological changes including elongation of prostatic urethral length. The aim of our study was to assess whether prostatic urethral le... This prospective observational study was conducted over a 12-months duration. All the patients who presented with lower urinary tract symptoms secondary to benign prostatic hyperplasia were evaluated ... A total of 153 patients were included in the study. Eighty-three (54.2%) patients underwent surgery during the study period. Prostate volume, intravesical prostatic protrusion, post-void residual volu... BPH patients with longer PUL may require surgical management. PUL measured by TRUS may be a predicting factor for the need of surgery in BPH Keywords: Benign prostatic hyperplasia; lower urinary tract...

Male Humans Prostate Prostatic Hyperplasia Prostate-Specific Antigen +2 autres

Clinicopathological and immunological profiles of prostate adenocarcinoma and neuroendocrine prostate cancer.

27 Dec 2022

DOI: 10.1186/s12957-022-02841-6 PMID: 36572885

Biomarkers of DNA damage repair deficiency provide opportunities for personalized treatment with immunotherapy. However, there is limited research on the immune microenvironment of adeno-neuroendocrin... A retrospective medical record review of 66 patients with prostate cancer (PCa) was performed. PCa samples from the 66 patients were analyzed using immunohistochemical staining for the detection of ch... Twenty patients presented with adeno-NEPC, whereas 46 presented with adeno-PCa. The median age of patients at PCa diagnosis was 67.86 ± 7.05 years (68.65 ± 7.23 years, adeno-NEPC; 67.52 ± 7.02 years, ... Our study revealed clinicopathological manifestations of adeno-NEPC and some possible predictive factors significantly associated with better outcomes in patients with adeno-NEPC. These findings might...

Male Humans Middle Aged Aged Prostatic Neoplasms +7 autres

The influence of prostate volume on clinical parameters in prostate cancer screening.

Oct 2022

DOI: 10.1002/jcla.24700 PMID: 36098911

The purpose of the study was to evaluate the diagnostic significance of two new and a few clinical markers for prostate cancer (PCa) at various prostate volumes (PV).... The study subjects were divided into two groups. Among them, there were 70 cases in the PV ≤30 ml group (benign prostatic hyperplasia [BPH]: 32 cases, PCa: 38 cases) and 372 cases in the PV > 30 ml gr... In the PV ≤30 ml group, the diagnostic parameters based on prostate-specific antigen (PSA) had a decreased diagnostic significance for PCa. In the PV > 30 ml group, PSAD (AUC = 0.709), AVR (AVR = Age/... Choosing appropriate indicators for different PVs could contribute to the early screening and diagnosis of PCa. The difference in the diagnostic value of two new indicators (A-PSAD and AVR), and PSAD ...

Biomarkers Early Detection of Cancer Humans Male Prostate +4 autres

Relationships between holmium laser enucleation of the prostate and prostate cancer.

04 2023

DOI: 10.1038/s41585-022-00678-y PMID: 36418491

Holmium laser enucleation of the prostate (HoLEP) is a size-independent surgical option for treating benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS) with excellent, durable ...

Male Humans Prostate Prostatic Hyperplasia Prostate-Specific Antigen +7 autres

Prostate health index (PHI) as an accurate prostate cancer predictor.

Sep 2023

DOI: 10.1007/s00432-023-04860-6 PMID: 37204514

This study aims to compare the ability of the PHI versus tPSA test to predict the presence of PCa in our population.... A prospective observational study was performed. We included patients with tPSA ≥ 2.5 ng/ml, biopsy naïve or previous negative biopsy, undergoing a blood test, which includes tPSA, fPSA, and p2PSA, an... 140 men were included. Fifty-seven (40.7%) had a positive prostate biopsy result (Group A), and 83 (59.3%) had a negative biopsy result (Group B). The mean age was similar in both groups (mean ± stand... The PHI test improves PCa detection compared to tPSA in our population....

Male Humans Prostate-Specific Antigen Prostate Prostatic Neoplasms +3 autres

Prostate Health Index Density Outperforms Prostate-specific Antigen Density in the Diagnosis of Clinically Significant Prostate Cancer in Equivocal Magnetic Resonance Imaging of the Prostate: A Multicenter Evaluation.

Jul 2023

DOI: 10.1097/JU.0000000000003450 PMID: 37036248

We compare Prostate Health Index, Prostate Health Index density, and PSA density in predicting clinically significant prostate cancer in MRI-guided prostate biopsy.... This is a multicenter evaluation of prospectively maintained prostate biopsy databases at 10 urology centers. Men with Prostate Health Index and MRI-guided targeted and systematic prostate biopsy perf... A total of 1,215 men were analyzed. Prostate cancer and clinically significant prostate cancer were diagnosed in 51% (617/1,215) and 35% (422/1,215) of men, respectively. Clinically significant prosta... Prostate Health Index density outperformed Prostate Health Index or PSA density in clinically significant prostate cancer detection in men with multiparametric MRI performed, and further reduced unnec...

Male Humans Prostatic Neoplasms Prostate Prostate-Specific Antigen +3 autres

Protein-tyrosine kinases : Questions médicales fréquentes

Termes MeSH sélectionnés :

Questions fréquentes et termes MeSH associés

Diagnostic 5

Symptômes 5

Prévention 5

Traitements 5

Complications 5

Facteurs de risque 5

Contenu validé par Dr Olivier Menir

Sous-catégories

Agammaglobulinaemia tyrosine kinase

Focal adhesion protein-tyrosine kinases

Janus kinases

Mitogen-Activated Protein Kinase Kinases

Syk kinase

src-Family kinases

ZAP-70 Protein-tyrosine kinase

Janus kinase 1

Janus kinase 3

TYK2 Kinase

MAP Kinase Kinase 1

MAP Kinase Kinase 2

MAP Kinase Kinase 3

MAP Kinase Kinase 4

MAP Kinase Kinase 5

MAP Kinase Kinase 6

MAP Kinase Kinase 7

CSK tyrosine-protein kinase

Auteurs principaux

Sources (10000 au total)